Back to today’s briefing

Story perspectives

Benchmark Holdings Sells Genetics Division for £260 Million

4/1/2025

38 8

Summary

Story summary

Benchmark Holdings has made a significant move by selling its genetics division to Novo Holdings for £260 million. This lucrative deal features an upfront payment of £230 million, with the potential for an additional £30 million based on future performance. After settling debts, Benchmark anticipates net cash proceeds of around £107.5 million, marking a pivotal moment for the company.

1 of 1

Story summary

Benchmark Holdings has made a significant move by selling its genetics division to Novo Holdings for £260 million. This lucrative deal features an upfront payment of £230 million, with the potential for an additional £30 million based on future performance. After settling debts, Benchmark anticipates net cash proceeds of around £107.5 million, marking a pivotal moment for the company.